Cargando…
C‐reactive protein : albumin ratio in patients with resectable intrahepatic cholangiocarcinoma
BACKGROUND: The C‐reactive protein : albumin ratio (CAR) has been reported as a novel prognostic marker in several cancers. The aim of this study was to investigate the prognostic value of CAR in patients with intrahepatic cholangiocarcinoma (ICC). METHODS: This was a single‐centre retrospective stu...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709369/ https://www.ncbi.nlm.nih.gov/pubmed/32959537 http://dx.doi.org/10.1002/bjs5.50348 |
_version_ | 1783617734479708160 |
---|---|
author | Matsumoto, T. Itoh, S. Yoshizumi, T. Kurihara, T. Yoshiya, S. Mano, Y. Takeishi, K. Harada, N. Ikegami, T. Soejima, Y. Baba, H. Mori, M. |
author_facet | Matsumoto, T. Itoh, S. Yoshizumi, T. Kurihara, T. Yoshiya, S. Mano, Y. Takeishi, K. Harada, N. Ikegami, T. Soejima, Y. Baba, H. Mori, M. |
author_sort | Matsumoto, T. |
collection | PubMed |
description | BACKGROUND: The C‐reactive protein : albumin ratio (CAR) has been reported as a novel prognostic marker in several cancers. The aim of this study was to investigate the prognostic value of CAR in patients with intrahepatic cholangiocarcinoma (ICC). METHODS: This was a single‐centre retrospective study of patients who underwent surgery for ICC in a university hospital in Japan between 1998 and 2018. CAR, Glasgow Prognostic Score (GPS) and modified GPS (mGPS) were calculated. Their correlation with recurrence‐free survival (RFS) and overall survival (OS) was analysed with Cox proportional hazards models. RESULTS: Seventy‐two patients were included in the study. Patients were divided into two groups according to the optimal CAR cut‐off value of 0·02. CAR above 0·02 was associated with higher carbohydrate antigen 19‐9 levels (20·5 versus 66·1 units/ml for CAR of 0·02 or less; P = 0·002), larger tumour size (3·2 versus 4·4 cm respectively; P = 0·031) and a higher rate of microvascular invasion (9 of 28 versus 25 of 44; P = 0·041). RFS and OS were shorter in patients with CAR above 0·02: hazard ratio (HR) 4·31 (95 per cent c.i. 2·02 to 10·63) and HR 4·80 (1·85 to 16·40) respectively. In multivariable analysis CAR above 0·02 was an independent prognostic factor of RFS (HR 3·29 (1·33 to 8·12); P < 0·001), but not OS. CONCLUSIONS: CAR was associated with prognosis in patients who had hepatic resection for ICC. |
format | Online Article Text |
id | pubmed-7709369 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley & Sons, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-77093692020-12-09 C‐reactive protein : albumin ratio in patients with resectable intrahepatic cholangiocarcinoma Matsumoto, T. Itoh, S. Yoshizumi, T. Kurihara, T. Yoshiya, S. Mano, Y. Takeishi, K. Harada, N. Ikegami, T. Soejima, Y. Baba, H. Mori, M. BJS Open Original Articles BACKGROUND: The C‐reactive protein : albumin ratio (CAR) has been reported as a novel prognostic marker in several cancers. The aim of this study was to investigate the prognostic value of CAR in patients with intrahepatic cholangiocarcinoma (ICC). METHODS: This was a single‐centre retrospective study of patients who underwent surgery for ICC in a university hospital in Japan between 1998 and 2018. CAR, Glasgow Prognostic Score (GPS) and modified GPS (mGPS) were calculated. Their correlation with recurrence‐free survival (RFS) and overall survival (OS) was analysed with Cox proportional hazards models. RESULTS: Seventy‐two patients were included in the study. Patients were divided into two groups according to the optimal CAR cut‐off value of 0·02. CAR above 0·02 was associated with higher carbohydrate antigen 19‐9 levels (20·5 versus 66·1 units/ml for CAR of 0·02 or less; P = 0·002), larger tumour size (3·2 versus 4·4 cm respectively; P = 0·031) and a higher rate of microvascular invasion (9 of 28 versus 25 of 44; P = 0·041). RFS and OS were shorter in patients with CAR above 0·02: hazard ratio (HR) 4·31 (95 per cent c.i. 2·02 to 10·63) and HR 4·80 (1·85 to 16·40) respectively. In multivariable analysis CAR above 0·02 was an independent prognostic factor of RFS (HR 3·29 (1·33 to 8·12); P < 0·001), but not OS. CONCLUSIONS: CAR was associated with prognosis in patients who had hepatic resection for ICC. John Wiley & Sons, Ltd 2020-09-21 /pmc/articles/PMC7709369/ /pubmed/32959537 http://dx.doi.org/10.1002/bjs5.50348 Text en © 2020 The Authors. BJS Open published by John Wiley & Sons Ltd on behalf of British Journal of Surgery Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Matsumoto, T. Itoh, S. Yoshizumi, T. Kurihara, T. Yoshiya, S. Mano, Y. Takeishi, K. Harada, N. Ikegami, T. Soejima, Y. Baba, H. Mori, M. C‐reactive protein : albumin ratio in patients with resectable intrahepatic cholangiocarcinoma |
title | C‐reactive protein : albumin ratio in patients with resectable intrahepatic cholangiocarcinoma |
title_full | C‐reactive protein : albumin ratio in patients with resectable intrahepatic cholangiocarcinoma |
title_fullStr | C‐reactive protein : albumin ratio in patients with resectable intrahepatic cholangiocarcinoma |
title_full_unstemmed | C‐reactive protein : albumin ratio in patients with resectable intrahepatic cholangiocarcinoma |
title_short | C‐reactive protein : albumin ratio in patients with resectable intrahepatic cholangiocarcinoma |
title_sort | c‐reactive protein : albumin ratio in patients with resectable intrahepatic cholangiocarcinoma |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709369/ https://www.ncbi.nlm.nih.gov/pubmed/32959537 http://dx.doi.org/10.1002/bjs5.50348 |
work_keys_str_mv | AT matsumotot creactiveproteinalbuminratioinpatientswithresectableintrahepaticcholangiocarcinoma AT itohs creactiveproteinalbuminratioinpatientswithresectableintrahepaticcholangiocarcinoma AT yoshizumit creactiveproteinalbuminratioinpatientswithresectableintrahepaticcholangiocarcinoma AT kuriharat creactiveproteinalbuminratioinpatientswithresectableintrahepaticcholangiocarcinoma AT yoshiyas creactiveproteinalbuminratioinpatientswithresectableintrahepaticcholangiocarcinoma AT manoy creactiveproteinalbuminratioinpatientswithresectableintrahepaticcholangiocarcinoma AT takeishik creactiveproteinalbuminratioinpatientswithresectableintrahepaticcholangiocarcinoma AT haradan creactiveproteinalbuminratioinpatientswithresectableintrahepaticcholangiocarcinoma AT ikegamit creactiveproteinalbuminratioinpatientswithresectableintrahepaticcholangiocarcinoma AT soejimay creactiveproteinalbuminratioinpatientswithresectableintrahepaticcholangiocarcinoma AT babah creactiveproteinalbuminratioinpatientswithresectableintrahepaticcholangiocarcinoma AT morim creactiveproteinalbuminratioinpatientswithresectableintrahepaticcholangiocarcinoma |